Free shipping on all orders over $ 500

Naquotinib mesylate

Cat. No. M14139
Naquotinib mesylate Structure

ASP8273 (mesylate)

Size Price Availability
5mg USD 105  USD105 1-2 Weeks
10mg USD 178  USD178 1-2 Weeks
25mg USD 365  USD365 1-2 Weeks
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Naquotinib mesylate (ASP8273 mesylate) is an orally available, mutant-selective and irreversible EGFR inhibitor; with IC50s of 8-33 nM toward EGFR mutants and 230 nM for EGFR.

Chemical Information
Molecular Weight 658.81
CAS Number 1448237-05-5
Solubility (25°C) DMSO 12.5 mg/mL
Storage 2-8°C, dry, sealed
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

Related EGFR/HER2 Products

ORM-5029 is a HER2/HER3-specific dual-targeted antibody degrader coupling (AnDC) for studies related to HER2-positive breast cancer.


CH7233163 is a non-covalent ATP-competitive EGFR- del19 /T790M/C797S inhibitor that can achieve potent inhibitory activity and mutation selection by exploiting multiple interactions with the αC helix conformation of EGFR, with antitumor activity, and can be used in studies related to non-small cell lung cancer (NSCLC).


BLU-701 is a highly selective, potent EGFR tyrosine kinase inhibitor (TKI) with activity against EGFR-activating mutations and C797S-resistant mutations for studies related to non-small cell lung cancer (NSCLC).


BI-4020 is a fourth-generation, orally active, non-covalent EGFR tyrosine kinase macrocyclic inhibitors (TKIs). It inhibits the triple mutant EGFR del19 T790M C797S mutant (IC50=0.2 nM in the BaF3 cell line), the double mutant EGFR del19 T790M, and the single mutant EGFR del19 (IC50=1 nM). and also retains activity against EGFR wt (IC50=190 nM), which can be used in studies related to non-small cell lung cancer (NSCLC).


BBT-176 is a novel, EGFR tyrosine kinase inhibitor (TKI) targeting the C797S mutation for studies related to non-small cell lung cancer (NSCLC).

Abmole Inhibitor Catalog

Keywords: Naquotinib mesylate, ASP8273 (mesylate) supplier, EGFR/HER2, inhibitors, activators

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.